United States securities and exchange commission logo

                          August 18, 2021

       Eliot Forster
       Chief Executive Officer
       F-star Therapeutics, Inc.
       Eddeva B920
       Babraham Research Campus
       Cambridge, CB22 3AT, United Kingdom

                                                        Re: F-star
Therapeutics, Inc.
Statement on Form S-3
                                                            Filed August 13,
                                                            File No. 333-258783

       Dear Dr. Forster:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact David
Gessert at 202-551-2326 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences